Publications by authors named "W G Armstrong"
Purpose: Blood-borne, cell-free DNA has been proposed as a means of individualizing the management of human papillomavirus (HPV)-positive oropharyngeal carcinoma.
Methods And Materials: This study was designed based on the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement. A comprehensive literature search of peer-reviewed publications from January 2013 to January 2024 was undertaken to identify prospective studies pertaining to the use of circulating HPV-DNA for oropharyngeal carcinoma.
Article Synopsis
- The study compares the definitions of high-volume disease (HVD) and low-volume disease (LVD) in metastatic hormone-sensitive prostate cancer (mHSPC) patients using both conventional imaging (CI) and prostate-specific membrane antigen (PSMA) PET imaging, highlighting the need for more accurate definitions for treatment decisions.
- Researchers analyzed data from 67 mHSPC patients across five international sites who had both PSMA PET and CI scans within a specific timeframe, assessing how many were classified as HVD or LVD based on each imaging method.
- Results showed a significant discrepancy in classification: 25.4% of patients were identified as HVD using CI, while 40.3% were identified as HVD using
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Purpose: To determine how smoking intensity impacts the prognosis of patients with human papillomavirus (HPV)-positive oropharyngeal cancer treated by chemoradiation.
Methods And Materials: The medical records of 32 patients with histologically proven squamous cell carcinoma of the oropharynx and a prior smoking history were retrospectively reviewed. All patients were treated with intensity-modulated radiotherapy to a median dose of 70 Gy (range 63 to 72 Gy) with concurrent cisplatin.